A retrospective study comparing survival outcomes with non-platinum (nab-paclitaxel, irinotecan) versus platinum based chemotherapy in patients with ERCC1 high locally advanced esophageal cancer

Next Previous
Trial Profile

A retrospective study comparing survival outcomes with non-platinum (nab-paclitaxel, irinotecan) versus platinum based chemotherapy in patients with ERCC1 high locally advanced esophageal cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Irinotecan
  • Indications Oesophageal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 03 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top